Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
about
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenThe aging spine: new technologies and therapeutics for the osteoporotic spineGiant osteoclast formation and long-term oral bisphosphonate therapyBisphosphonates: mechanism of action and role in clinical practiceIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisGuidelines on the management of osteoporosis associated with chronic liver diseaseDrugs in development: bisphosphonates and metalloproteinase inhibitorsEffect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonatesSkeletal lead release during bone resorption: effect of bisphosphonate treatment in a pilot studyManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchCalcium intake and bone mineral density: systematic review and meta-analysisOsteoporosis Treatment: When to Discontinue and When to Re-startConsequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursorsTreatment of primary osteoporosis in menBone mass and mineral metabolism alterations in adult celiac disease: pathophysiology and clinical approachHepatic osteodystrophyDenosumab for the treatment of osteoporosisParathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosisBisphosphonates: from bench to bedsideUpdate on bazedoxifene: a novel selective estrogen receptor modulatorPlacebo orthodoxy in clinical research. I: Empirical and methodological mythsEffect of intravenous pamidronate on bone mineral density in adults with cystic fibrosisThe effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancerControlled delivery of zoledronate improved bone formation locally in vivoImpact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatmentSynthesis of composite magnetic nanoparticles Fe3O4 with alendronate for osteoporosis treatmentUsing GWAS to identify novel therapeutic targets for osteoporosis.Computer-aided diagnosis in medical imaging: historical review, current status and future potentialAlterations of mass density and 3D osteocyte lacunar properties in bisphosphonate-related osteonecrotic human jaw bone, a synchrotron µCT study.Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures.Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone.Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials.Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.Changing perceptions in osteoporosis.Prevention of hip fractures in long-term care: relevance of community-derived data.Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study.Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.
P2860
Q24242258-82A02B47-F586-413C-A307-2F628727C332Q24609687-C96EDE60-5CC6-4973-8F51-CAD901F53DAEQ24626459-FD90F346-370A-4609-BBEA-686CE465C0A8Q24644708-A8E85577-919B-4BA6-8823-DFF12CAEC355Q24680238-21B5B57D-1849-4DA9-AF14-6AC75EDA5EB0Q24685899-564CAF41-DB1B-4774-BD48-964963F166A0Q24795847-1D70513F-08C8-46BA-BF75-3C38D7991962Q24802074-DC25878B-94D3-4C30-86B7-D1C828FF8AF4Q24810911-283F908E-1492-470E-834D-31B7814C3FE4Q26782621-DA0DDA59-D32D-431F-B533-38C1F361D7C8Q26784337-F77A2DA7-7D99-4EF2-BB50-F0CD642D857BQ26858980-C11F6AA6-B934-4B53-94E5-1E8F6BF5A211Q26864483-64D73BC1-3DAC-4569-AAEF-B7C02686B87EQ26991748-E542710F-A8ED-43D9-BDC7-269997672A7FQ26997909-7DC17678-7744-44C9-8F3E-6971DAC330D3Q27004571-CAA2DC54-6605-4D71-95BF-91CE76F9F87DQ27009275-62D18BC2-76CA-4ED9-B806-7841FCA3F215Q27024513-3BDADCC4-9645-4AF3-8EB2-12001475F4C0Q28251212-138BC435-E514-4B6C-B902-4C70C196C42DQ28258998-E8F67A06-F761-45FA-A317-71DBB609CEE3Q28305894-E4E36628-B190-4E1A-B6E7-412B8653111BQ28360554-98C325D1-8848-43CE-BE35-C455424641DEQ28362960-05D402F2-783B-4FCF-A851-4DA26363885EQ28540762-94ED9F4B-8864-487C-9E16-AF6E551AC415Q28731336-0A34E86B-62AB-4543-A533-5764E9F370B2Q28829845-868D91E9-E199-4897-8797-0163F9A96234Q30275429-7CE3BD1E-96C8-4A0E-9687-0FDA84BDFF18Q30360316-E13BBF83-6EB3-4861-A3D2-0BE7F43F7481Q30442689-11C6CC96-0CEF-4E60-88B9-0A04381026ADQ30476509-ADE69B2D-ED68-4BBC-B209-7694AC934864Q30627873-B023B463-6E43-4DB4-9237-E60CA28C7B06Q30755058-983F23D2-4C8D-4FD1-B445-3137A005DCEDQ31048716-AF08F6C2-13F4-477A-95FE-53B452CF9823Q31162221-D216A392-2397-464E-9C39-5FF242787162Q32045038-347FDF7F-3A33-429C-A06C-B8AE10EBDAFEQ33305959-B43EF811-E71E-4D31-B6CC-388BEB0D35E2Q33545020-6DD209DD-3B33-4700-8844-2D643B4AA4B5Q33546626-BEB371D8-7D50-4F02-B006-E9E9E9BDE147Q33553938-D801B579-DC61-40E8-92F1-BA7510BA44F7Q33569806-51449A3A-7F22-4084-984C-6C904AAA2E51
P2860
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Effect of oral alendronate on ...... porosis Treatment Study Group.
@en
Effect of oral alendronate on ...... porosis Treatment Study Group.
@nl
type
label
Effect of oral alendronate on ...... porosis Treatment Study Group.
@en
Effect of oral alendronate on ...... porosis Treatment Study Group.
@nl
prefLabel
Effect of oral alendronate on ...... porosis Treatment Study Group.
@en
Effect of oral alendronate on ...... porosis Treatment Study Group.
@nl
P2093
P1476
Effect of oral alendronate on ...... porosis Treatment Study Group.
@en
P2093
Dequeker J
Downs RW Jr
Liberman UA
Rodriguez-Portales J
P304
P356
10.1056/NEJM199511303332201
P407
P577
1995-11-01T00:00:00Z